Antidepressant use during pregnancy

Ariela Frieder

Research output: Contribution to journalArticle

Abstract

Depression during pregnancy affects 10-20% of pregnant women and can have detrimental effects (short and long term) for the mother, fetus and family. The use of antidepressants during pregnancy has been the subject of much debate. Recent data suggest a possible risk to the fetus with maternal use of antidepressants. Selective serotonin reuptake inhibitors have been associated with congenital malformations, negative pregnancy outcomes, neonatal behavioral symptoms and persistent pulmonary hypertension of the newborn. Women with depression tend to discontinue their medication when trying to conceive or upon discovering they are pregnant, placing themselves at increased risk of recurrence of their affective illness. Therefore, it is important for clinicians to understand the risks and benefits of antidepressant use during pregnancy in order to appropriately counsel women. The purpose of this article is to review updated information regarding the use of antidepressants during pregnancy.

Original languageEnglish (US)
Pages (from-to)285-294
Number of pages10
JournalExpert Review of Obstetrics and Gynecology
Volume6
Issue number3
DOIs
StatePublished - May 2011

Fingerprint

Antidepressive Agents
Pregnancy
Fetus
Mothers
Persistent Fetal Circulation Syndrome
Depression
Behavioral Symptoms
Serotonin Uptake Inhibitors
Pregnancy Outcome
Pregnant Women
Recurrence

Keywords

  • antidepressants
  • birth outcomes
  • depression
  • malformations
  • pregnancy
  • selective serotonin reuptake inhibitors

ASJC Scopus subject areas

  • Obstetrics and Gynecology
  • Reproductive Medicine
  • Maternity and Midwifery
  • Pediatrics, Perinatology, and Child Health

Cite this

Antidepressant use during pregnancy. / Frieder, Ariela.

In: Expert Review of Obstetrics and Gynecology, Vol. 6, No. 3, 05.2011, p. 285-294.

Research output: Contribution to journalArticle

Frieder, Ariela. / Antidepressant use during pregnancy. In: Expert Review of Obstetrics and Gynecology. 2011 ; Vol. 6, No. 3. pp. 285-294.
@article{8cf56f84f8134913bca499c780eeac4e,
title = "Antidepressant use during pregnancy",
abstract = "Depression during pregnancy affects 10-20{\%} of pregnant women and can have detrimental effects (short and long term) for the mother, fetus and family. The use of antidepressants during pregnancy has been the subject of much debate. Recent data suggest a possible risk to the fetus with maternal use of antidepressants. Selective serotonin reuptake inhibitors have been associated with congenital malformations, negative pregnancy outcomes, neonatal behavioral symptoms and persistent pulmonary hypertension of the newborn. Women with depression tend to discontinue their medication when trying to conceive or upon discovering they are pregnant, placing themselves at increased risk of recurrence of their affective illness. Therefore, it is important for clinicians to understand the risks and benefits of antidepressant use during pregnancy in order to appropriately counsel women. The purpose of this article is to review updated information regarding the use of antidepressants during pregnancy.",
keywords = "antidepressants, birth outcomes, depression, malformations, pregnancy, selective serotonin reuptake inhibitors",
author = "Ariela Frieder",
year = "2011",
month = "5",
doi = "10.1586/eog.11.24",
language = "English (US)",
volume = "6",
pages = "285--294",
journal = "Expert Review of Obstetrics and Gynecology",
issn = "1747-4108",
publisher = "Expert Reviews Ltd.",
number = "3",

}

TY - JOUR

T1 - Antidepressant use during pregnancy

AU - Frieder, Ariela

PY - 2011/5

Y1 - 2011/5

N2 - Depression during pregnancy affects 10-20% of pregnant women and can have detrimental effects (short and long term) for the mother, fetus and family. The use of antidepressants during pregnancy has been the subject of much debate. Recent data suggest a possible risk to the fetus with maternal use of antidepressants. Selective serotonin reuptake inhibitors have been associated with congenital malformations, negative pregnancy outcomes, neonatal behavioral symptoms and persistent pulmonary hypertension of the newborn. Women with depression tend to discontinue their medication when trying to conceive or upon discovering they are pregnant, placing themselves at increased risk of recurrence of their affective illness. Therefore, it is important for clinicians to understand the risks and benefits of antidepressant use during pregnancy in order to appropriately counsel women. The purpose of this article is to review updated information regarding the use of antidepressants during pregnancy.

AB - Depression during pregnancy affects 10-20% of pregnant women and can have detrimental effects (short and long term) for the mother, fetus and family. The use of antidepressants during pregnancy has been the subject of much debate. Recent data suggest a possible risk to the fetus with maternal use of antidepressants. Selective serotonin reuptake inhibitors have been associated with congenital malformations, negative pregnancy outcomes, neonatal behavioral symptoms and persistent pulmonary hypertension of the newborn. Women with depression tend to discontinue their medication when trying to conceive or upon discovering they are pregnant, placing themselves at increased risk of recurrence of their affective illness. Therefore, it is important for clinicians to understand the risks and benefits of antidepressant use during pregnancy in order to appropriately counsel women. The purpose of this article is to review updated information regarding the use of antidepressants during pregnancy.

KW - antidepressants

KW - birth outcomes

KW - depression

KW - malformations

KW - pregnancy

KW - selective serotonin reuptake inhibitors

UR - http://www.scopus.com/inward/record.url?scp=79959227913&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=79959227913&partnerID=8YFLogxK

U2 - 10.1586/eog.11.24

DO - 10.1586/eog.11.24

M3 - Article

AN - SCOPUS:79959227913

VL - 6

SP - 285

EP - 294

JO - Expert Review of Obstetrics and Gynecology

JF - Expert Review of Obstetrics and Gynecology

SN - 1747-4108

IS - 3

ER -